EN DE
Watch Nuvectis Pharma Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Nuvectis Pharma Inc (NVCT) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Nuvectis Pharma Inc stock $14.10, price $21.08, that is 33.1% below the price, quality 46 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

NP Nuvectis Pharma Inc logo Thin data Nov 10, 2026

Nuvectis Pharma Inc

NVCT · US
Expensive, weak quality

Our calculation puts a fair price 33% below what the stock costs today.

Quality 46/100
Mixed vs. peers (3/7)
Insiders bought $250,000 (6M)
Fair value $14.10 · Overvalued
Weak Growth
Negative free cash flow
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch Nuvectis Pharma Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$28.53 $3.25 Fair Value $14.10 Feb 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

57‑month range $3.25 – $28.53 · fair‑value band $10.58 – $17.63 · the $21.08 price screens above the $14.10 fair value. As of Nov 10, 2026.

Follow Nuvectis Pharma in your weekly email

Every Wednesday you see whether Nuvectis Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology.

Show moreShow less

The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021.

Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Stock analysis

Nuvectis Pharma Inc (NVCT) currently trades at $21.08, while our estimate is $14.10, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $10.58 (bear) to $17.63 (bull), the price of $21.08 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Nuvectis Pharma Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$26.4M in FY2025.

Key figures

Market cap $725M Small · EPS (TTM) $−2.00 · Return on equity −67.0% · Return on assets (EBIT) −120% (5-year average) · Free cash flow −$16.0M · Net cash $31.6M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 26% below its 52-week high and 263% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −33%, NVCT screens richer than that median.

Fair Value

Bear $10.58 Fair Value $14.10 Bull $17.63
Price $21.08 · Downside -33.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 46/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 54
Do the profits arrive as real cash?
Financial strength 97
Debt, balance sheet and risk of trouble
Investment 38
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 87
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 84
Distance to the 52-week high, does not count
New shares 2
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $250,000, on Jun 30, 2026.

  • BuyRon BentsurChairman & CEO, Director, 10% owner12,500 shares at $20.00$250,000Jun 30, 2026
  • BuyMarlio Charles Mosseri10% owner50,000 shares at $18.32$916,000Jun 30, 2026

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NVCT screens overvalued: fair value 33% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Nuvectis Pharma Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 46 · Above median
Fair Value upside −33.1% · Below median
Profitability
Return on assets −83.4% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 39.37× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs NVCT
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs NVCT
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs NVCT
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs NVCT
argenx SE ARGX $971.55 $908.40 −7% vs NVCT
CSL Limited CSL A$201.68 A$181.40 −10% vs NVCT
Moderna, Inc MRNA $250.83 $158.70 −37% vs NVCT
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs NVCT
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs NVCT
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs NVCT

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Nuvectis Pharma Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Nuvectis Pharma Inc Fair Value". https://www.fairvalue-calculator.com/stock/NVCT

Frequently asked questions

Is Nuvectis Pharma Inc (NVCT) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $14.10 versus a price of $21.08, about 33% lower (overvalued).
What is the fair value of NVCT?
Our estimate for Nuvectis Pharma Inc is $14.10 (as of Nov 10, 2026), built from audited fundamentals. The current price: $21.08.
What is the quality score of NVCT?
Nuvectis Pharma Inc has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Nuvectis Pharma Inc (NVCT)?
Our calculated price target is the estimate of $14.10 (as of Nov 10, 2026). Cautious scenario $10.58, optimistic scenario $17.63. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Nuvectis Pharma Inc stock forecast for 2026?
Our estimate puts fair value at $14.10, about 33% lower versus a price of $21.08 (overvalued). Cautious scenario $10.58, optimistic scenario $17.63. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Nuvectis Pharma Inc (NVCT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Nuvectis Pharma Inc it is $14.10 per share (as of Nov 10, 2026), against a price of $21.08.
Is Nuvectis Pharma Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, NVCT trades above its calculated fair value: price $21.08, fair value $14.10, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NVCT?
No. The price is what the market pays today ($21.08); the fair value is what the company's own numbers justify ($14.10). For Nuvectis Pharma Inc the two are $6.98 per share apart. That gap is exactly why we show both numbers side by side.
How much is Nuvectis Pharma Inc worth?
The market values Nuvectis Pharma Inc at about $725M (market capitalisation, as of Nov 10, 2026). Per share that is $21.08; our models calculate a fair value of $14.10 per share.
What do the bullish and bearish scenarios say about NVCT?
Our models span a range for Nuvectis Pharma Inc: cautious scenario $10.58, base $14.10, optimistic $17.63 per share (as of Nov 10, 2026, price $21.08). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Nuvectis Pharma Inc (NVCT)?
Balance-sheet figures for Nuvectis Pharma Inc (as of Nov 10, 2026): return on equity −67.0%. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is NVCT from its 52-week high?
Nuvectis Pharma Inc trades at $21.08, about 26% below its 52-week high of $28.53 and 263% above the low of $5.81 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $14.10 is for.
Which stocks are comparable to Nuvectis Pharma Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Nuvectis Pharma Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $21.08, calculated fair value $14.10 (−33%), Quality Score 46/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Nuvectis Pharma Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Nuvectis Pharma Inc (NVCT)?
The closing price on Nov 10, 2026 was $21.08. Our estimate is $14.10, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Nuvectis Pharma Inc right now?
The price sits above even our optimistic bull case ($17.63). The favourable scenario is already priced in. Weak quality (46/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Nuvectis Pharma Inc

How large is the market capitalisation of Nuvectis Pharma Inc (NVCT)?
The market capitalisation of Nuvectis Pharma Inc is $725M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Nuvectis Pharma Inc (NVCT)?
Earnings per share at Nuvectis Pharma Inc are $−2.00. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Nuvectis Pharma Inc (NVCT)?
The return on equity (ROE) of Nuvectis Pharma Inc is −67.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Nuvectis Pharma Inc (NVCT)?
On an EBIT basis the return on assets of Nuvectis Pharma Inc is −120% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Nuvectis Pharma Inc (NVCT) generate?
The free cash flow of Nuvectis Pharma Inc is −$16.0M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Nuvectis Pharma Inc (NVCT) hold?
Nuvectis Pharma Inc holds more cash than debt, $31.6M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Nuvectis Pharma Inc in the live analysis

One click puts Nuvectis Pharma Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.